Search results
Jul 17, 2024 · Summary. AbbVie Inc. will announce its Q2 2024 earnings next Thursday, 25th July. The company has a new CEO, with insider Rob Michael taking the reins after long-term CEO Rick Gonzalez's retirement.
Jun 14, 2024 · AbbVie agrees $1.7bn deal with China's FutureGen to license an anti-TL1A inflammatory bowel disease therapy still in preclinical development
3 days ago · AbbVie had revenue of $54.40B in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $12.31B with 0.70% year-over-year growth.
Jul 15, 2024 · AbbVie Inc. ABBV announced that it has submitted regulatory applications to the FDA and the European Medicines Agency (EMA), seeking approval for its JAK inhibitor, Rinvoq (upadacitinib), for a ...
Jul 11, 2024 · AbbVie ABBV stock has gained 24.0% compared with an increase of 34.3% for the industry in the past year, as seen in the chart below. Image Source: Zacks Investment Research AbbVie lost patent ...
1 day ago · AbbVie (NYSE: ABBV) stock was the cure for what ails a portfolio on Thursday. The sturdy pharmaceutical company was a favorite of investors, who were trading its shares up by nearly 4% in price in ...
1 day ago · AbbVie reported strong sales of its other medicines as demand for Humira fell because of competition from biosimilar drugs. Revenue from rheumatoid arthritis medicines Rinvoq and Skyrizi soared ...
